Pfizer Animal Health
Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza3 Vaccine
Modified Live Virus
Campylobacter Fetus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin
PRODUCT DESCRIPTION: PregGuard GOLD FP 10 is for vaccination of healthy cows and heifers prior to breeding as an aid in preventing abortion caused by infectious bovine rhinotracheitis (IBR, bovine herpesvirus Type 1) virus; persistently infected calves caused by bovine virus diarrhea (BVD) virus Types 1 and 2; respiratory disease caused by IBR, BVD Types 1 and 2, and parainfluenza3 (PI3) virus; BVD Type 2 testicular infection; campylobacteriosis (vibriosis) caused by Campylobacter fetus; and leptospirosis caused by Leptospira canicola, L. grippotyphosa, L. hardjo, L. icterohaemorrhagiae, and L. pomona. A 12-month duration of immunity has been demonstrated against IBR-induced abortion and persistently infected calves caused by BVD Types 1 and 2. PregGuard GOLD FP 10 may be administered to pregnant cattle provided they were vaccinated, according to label directions, with any Bovi-Shield® FP or PregGuard FP vaccine within the past 12 months. PregGuard GOLD FP 10 may also be administered to calves nursing pregnant cows provided their dams were vaccinated within the past 12 months as described above. The freeze-dried vaccine is a preparation of modified live virus (MLV) strains of IBR, BVD (Types 1 and 2), and PI3 propagated on an established cell line. The Campylobacter bacterin is an inactivated suspension of C. fetus. It is combined with an inactivated Leptospira bacterin prepared from whole cultures of the agents indicated. The Campylobacter-Leptospira bacterin is supplied as a diluent for the IBR-BVD-PI3 vaccine.
DISEASE DESCRIPTION: IBR, BVD, and PI3 viruses are commonly associated with respiratory disease and/or reproductive failure in cattle. IBR virus infection is characterized by high temperature, excessive nasal discharge, conjunctivitis and ocular discharge, inflamed nose (“red nose”), increased rate of respiration, coughing, loss of appetite, and depression. Cattle infected during pregnancy may abort.
BVD virus may be transmitted in nasal secretions, saliva, blood, feces, and/or urine, and by direct contact with contaminated objects; it invades through the nose and mouth and replicates systemically. Infection during pregnancy may result in abortion, fetal resorption, or congenital malformation of the fetus. Moreover, if susceptible cows are infected with noncytopathic BVD virus during the first trimester of pregnancy, their calves may be born persistently infected with the virus. Exposure of those calves to certain virulent cytopathic BVD virus strains may precipitate BVD-mucosal disease. Both BVD Types 1 and 2 can show a variety of clinical signs. The signs may be mild and not readily apparent. Clinical signs may include severe immune suppression, diarrhea, anorexia, depression, fever and respiratory disease. If infected with some Type 2 strains of BVD, severe thrombocytopenia may occur and hemorrhaging may be seen.
PI3 virus usually localizes in the upper respiratory tract, causing elevated temperature and moderate nasal and ocular discharge. Although clinical signs typically are mild, PI3
infection weakens respiratory tissues. Invasion and replication of other pathogens, particularly Pasteurella spp., is thereby facilitated and may result in pneumonia.
Campylobacteriosis (vibriosis) is an insidious venereal disease of cattle. The Campylobacter organism infects the cow's genital tract causing early embryonic death. The disease is characterized by infertility, repeat breeding, and a prolonged calving season.
Leptospirosis may be caused by several serovars of Leptospira, of which L. canicola, L. grippotyphosa, L. hardjo, L. icterohaemorrhagiae, and L. pomona are the most common affecting cattle. Leptospira localize in the kidneys, are shed in the urine, and cause anemia, bloody urine, fever, loss of appetite, and prostration in calves. Signs are usually subclinical in adult cattle. Infected pregnant cows, however, often abort, and dairy cows may exhibit a marked decrease in milk production. Leptospira spp. are known zoonotic pathogens.
SAFETY AND EFFICACY: The cell lines on which the modified live virus fractions are produced have been extensively tested to ensure freedom from adventitious agents. Two studies were conducted demonstrating the safety of the BVD Type 2 fraction of PregGuard GOLD FP 10. In the first study 14- to 15-month-old crossbred beef calves negative for BVD virus and BVD neutralizing antibodies, and with no history of BVD vaccination, were given a field dose of the BVD Type 2 strain intramuscularly. Susceptible contact control animals maintained in this study did not seroconvert to BVD. In the second study, 4- to 8-week-old, colostrum-deprived crossbred beef calves, negative for BVD virus and BVD neutralizing antibodies, were given a field dose of the BVD Type 2 strain intranasally. In both studies, no clinical signs attributable to BVD infection were observed, and attempts to re-isolate the vaccine virus from nasal secretions were unsuccessful.
The safety of the fractions of PregGuard GOLD FP 10 was demonstrated in 2 field safety studies, each at different geographic locations, utilizing a total of 399 animals. Safety was evaluated in 6- to 8-month-old beef calves in a feedlot environment, in 3- to 7-month-old beef calves prior to weaning. No injection site, serious systemic or allergic reactions or clinical abnormalities attributable to vaccination were observed.
Three additional field studies demonstrated the safety of PregGuard GOLD FP 10 when administered to pregnant cows previously vaccinated with one of the Bovi-Shield FP or PregGuard FP products. In all three studies, cows were vaccinated with either Bovi-Shield FP 4+L5 or PregGuard FP 9 between 12 and 17 months prior to vaccination with either Bovi-Shield GOLD FP 5 VL5 or placebo during the first, second, or third trimester of pregnancy. The pregnancy status of cows vaccinated during the first trimester of pregnancy was determined approximately 3 months postvaccination. Pregnancy was confirmed in 197 of 198 (99.5%) placebo-vaccinated cows and 198 of 200 (99%) cows vaccinated with Bovi-Shield GOLD FP 5 VL5.
Cows vaccinated during the second or third trimester of pregnancy were observed through calving, and the health status of their newborn calves was determined. Second trimester vaccination resulted in the delivery of healthy calves in 149 of 150 (99.3%) placebo vaccinates, and in 162 of 164 (98.8%) cows vaccinated with Bovi-Shield GOLD FP 5 VL5. One hundred percent of cows vaccinated with placebo (138 of 138) and Bovi-Shield (184 of 184) during the third trimester of pregnancy delivered healthy calves.
The effectiveness of the IBR and BVD fractions of PregGuard GOLD FP 10 as an aid in preventing abortion caused by IBR and persistently infected calves caused by BVD (Types 1 & 2) was demonstrated in multiple IBR, BVD Type 1, and BVD Type 2 challenge-of-immunity studies, including studies demonstrating that PregGuard GOLD FP 10 protected pregnant cows and their fetuses for one year following vaccination. Heifers were challenged with BHV-1, BVD Type 1 or BVD Type 2 viruses at least 365 days following vaccination. Following challenge with BHV-1 virus, 100% of placebo vaccinated control cows aborted, compared to 15.8% of vaccinates. Following challenge with BVD Type 1 virus, 100% of fetuses born to vaccinated cows were protected from persistent BVD infection, compared to 12% of calves born to placebo-vaccinated control cows. Similarly, following BVD Type 2 challenge, 90% of calves from vaccinated heifers were protected, while 0% of calves from placebo-vaccinated control cows were protected.
The efficacy of PregGuard GOLD FP 10 in preventing BVD Type 2 testicular infection was demonstrated in a vaccination-challenge study. Following challenge with BVD Type 2 (28 days postvaccination), 84.7% of testicular samples from nonvaccinated controls were positive, while none of vaccinated calves' samples were BVD positive.
General Directions: Vaccination of healthy cattle is recommended. Aseptically rehydrate the freeze-dried vaccine (PregGuard GOLD FP) with the liquid bacterin provided (Vibrio/Leptoferm-5™), shake well, and administer 2 mL intramuscularly. In accordance with Beef Quality Assurance guidelines, this product should be administered in the muscular region of the neck.
Primary Vaccination: Administer a single 2-mL dose to all breeding cows and heifers approximately 1 month prior to breeding or being added to the herd, followed 2-4 weeks later by a single dose of Vibrio/Leptoferm-5.
Revaccination: Annual revaccination with a single dose of PregGuard GOLD FP 10 is recommended.
Good animal husbandry and herd health management practices should be employed.
Do not use in pregnant cows (abortions can result) unless they were vaccinated, according to label directions, with any Bovi-Shield FP or PregGuard FP vaccine within the past 12 months. Do not use in calves nursing pregnant cows unless their dams were vaccinated within the past 12 months as described above. Do not vaccinate calves under 3 months of age.
Consistent with good vaccination practices, it is recommended that heifers receive at least 2 doses with the second dose administered approximately 30 days prebreeding.
Store at 2°-7°C. Prolonged exposure to higher temperatures and/or direct sunlight may adversely affect potency. Do not freeze.
Use entire contents when first opened.
Sterilized syringes and needles should be used to administer this vaccine. Do not sterilize with chemicals because traces of disinfectant may inactivate the vaccine.
Burn containers and all unused contents.
Do not vaccinate within 21 days before slaughter.
Contains gentamicin as preservative.
Vaccination of stressed animals should be delayed.
Occasional hypersensitivity reactions may occur up to 18 hours postvaccination. Owners should be advised to observe animals during this period. While this event appears to be rare overall, dairy cattle may be affected more frequently than other cattle. Animals affected may display excessive salivation, incoordination, and/or dyspnea. Animals displaying such signs should be treated immediately with epinephrine or equivalent. In non-responsive animals, other modes of treatment should be considered.
As with many vaccines, anaphylaxis may occur after use. Initial antidote of epinephrine is recommended and should be followed with appropriate supportive therapy.
This product has been shown to be efficacious in healthy animals. A protective immune response may not be elicited if animals are incubating an infectious disease, are malnourished or parasitized, are stressed due to shipment or environmental conditions, are otherwise immunocompromised, or the vaccine is not administered in accordance with label directions.
Technical inquiries should be directed to Pfizer Animal Health Veterinary Services, (800) 366-5288 (USA), (800) 461-0917 (Canada).
For veterinary use only
U.S. Veterinary License No. 189
Pfizer Animal Health, Exton, PA 19341, USA, Div. of Pfizer Inc, NY, NY 10017
Presentation: 10 and 50 dose vials.
NAC No.: 36902112